The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
The committee released the 1,180-page text of its changes to the House-passed Build Back Better Act on Saturday. Groups and law firms that represent 340B entities said yesterday they were still studying the Finance Committee text and seeking more information before reaching conclusions about its implications for 340B program participants.
The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.